31-05-2025
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardant Health (GH – Research Report), AnaptysBio (ANAB – Research Report) and Alignment Healthcare (ALHC – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Guardant Health (GH)
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health, with a price target of $60.00. The company's shares closed last Monday at $44.05.
According to Westenberg is a 3-star analyst with an average return of 3.1% and a 44.4% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Elanco Animal Health, and Pacific Biosciences.
Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $59.26, which is a 29.4% upside from current levels. In a report issued on April 22, Leerink Partners also maintained a Buy rating on the stock.
AnaptysBio (ANAB)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on AnaptysBio, with a price target of $57.00. The company's shares closed last Monday at $20.73.
According to Rahimi is a 1-star analyst with an average return of -1.0% and a 34.8% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Praxis Precision Medicines.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio with a $45.57 average price target, which is a 120.2% upside from current levels. In a report issued on April 22, Wells Fargo also maintained a Buy rating on the stock with a $51.00 price target.
Alignment Healthcare (ALHC)
In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Alignment Healthcare, with a price target of $21.00. The company's shares closed last Monday at $15.48.
According to Tassan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.8% and a 39.2% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Privia Health Group, Health Catalyst, and Evolent Health.
Currently, the analyst consensus on Alignment Healthcare is a Moderate Buy with an average price target of $18.35, implying a 18.6% upside from current levels. In a report issued on May 2, TD Cowen also maintained a Buy rating on the stock with a $17.00 price target.
